RFCA
PGNX

R&F Capital Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

R&F Capital Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,119
Closed -$96K – 876
2016
Q4 		$96K Buy
+11,119
New +$82.2K 0.03% 452

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

R&F Capital Advisors's PGNX Position: Q1 2017 in Review

R&F Capital Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2017, closing a stake of 11,119 shares — an estimated $96K sold.

R&F Capital Advisors first reported a position in PGNX in Q4 2016 and held it in 1 quarter. The position peaked at $96K in Q4 2016. 159 funds tracked by Wall St. Rank hold PGNX as of Q1 2017.

  • R&F Capital Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 11,119 Progenics Pharmaceuticals Inc shares in Q1 2017, an estimated $96K.
  • R&F Capital Advisors first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Progenics Pharmaceuticals Inc position peaked at $96K in Q4 2016.
  • 159 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.